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INTRODUCTION
The prevalence of cardiovascular disease (CVD) 
in patients with diabetes mellitus (DM) is by two-four 
times higher and represents the leading cause for death 
in them. Classical CVD risk factors such as tobacco 
smoking, hypertension, hypercholesterolaemia and 
obesity are not sufficient to explain this increasing 
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risk for DM patients anymore (11). Researchers 
are focusing on investigating new risk factor such 
as factors of the oxidative stress, free radicals, 
some metabolites and hormones like testosterone. 
Hyperhomocysteinaemia and hs-CRP are non-
classical risk factors independently associated to CVD 
development. Althouigh the importance of the acute 
phase protein in its low concentrations known as hs-
CPR is proved in many studies, data about the role 
of homocysteine (Hcy) in predicting CHD remains 
controversial, especially in specific groups of patient 
like those with type 2 DM (DMT2). 
The therapeutic possibilities for lowering 
serum Hcy levels are well-known and very attractive 
to scientists. One still looks for the answer of the 
question whether hyperhomocysteinaemia is the 
cause or the effect of ongoing atherogenesis. 
ABSTRACT
PURPOSE: Hyperhomocysteinaemia and hs-CRP are non-classical risk factors independently associated to 
the development of cardiovascular disease. The increased coronary heart disease (CHD) risk in subjects with 
type 2 diabetes mellitus (DMT2) can be in part explained by the classical risk factors like hypertension, hy-
perlipidemia and obesity. There is no sufficient data about the importance of homocysteine (Hcy) and hs-
CRP levels in DMT2 patients without CHD in predicting the macroangiopathic complications. The aim of 
this study was to determine the association between plasma homocysteine and hs-CRP concentrations in 
DMT2 patients with and without CHD.
MATERIAL AND METHODS: Fifty patients hospitalized in the Clinic of Endocrinology at St. Marina Uni-
versity Hospital of Varna were divided into three groups: group one, 20 DMT2 patients without any evidence 
of CHD; group two, 20 DMT2 patients with history of CHD and group three, 10 healthy controls matched to 
these groups in terms of age and classical risk factors for CHD.
RESULTS: Serum hs-CRP concentrations were significantly higher in DMT2 patients than in healthy con-
trols as well as in DMT2 patients with CHD than in CHD-free DMT2 ones. Serum Hcy concentrations were 
significantly higher in DMT2 patient with CHD than in controls. Both markers were elevated in group two 
presenting with the highest risk for CHD.
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Hcy is a sulphur-containing amino acid in 
the body produced by conversion of methionine, 
an essential amino acid present in foods regularly 
consumed within the diet. Low Hcy levels (5-15 
μmol/L) are normally found in plasma (5). However, 
genetic defects in the enzymes of Hcy metabolism 
markedly increase Hcy levels. Studies in animal 
models show that elevated  Hcy levels result in 
increased oxidative stress (3,9), impaired endothelial 
function (10,12) and increased thrombogenicity (10), 
which act together to promote atherosclerosis (4).
Some investigations demonstrate that plasma 
Hcy levels are elevated in CVD patients with and 
without DM. However, the results dealing with 
the relationship between plasma Hcy levels and 
CVD in DMT2 patients are controversial. Some 
studies report slightly elevated Hcy levels in DMT2 
patients with CHD and low or normal levels in 
DMT1 ones, which leads to the conclusion that 
Hcy levels do not influence on CHD prevalence in 
DM patients (2,8). Other investigations prove that 
hyperhomocysteineaemia is an independent risk 
factor for CHD in DMT2 patients when compared to 
those without DM (7,8).
The aim of this study was to determine the 
association between plasma homocysteine and hs-
CRP concentrations in DMT2 patients with and 
without CHD.
MATERIAL AND METHODS
After approval of the study protocol by the local 
ethical committee, the study was conducted in the 
Central Clinical Laboratory and Clinic of Endocrinology 
at St. Marina University Hospital of Varna. Inclusion 
criterion was diagnosis of DMT2 according to World 
Health Organization (WHO) criteria for at least 2 years. 
Exclusion criteria were previously recorded myocardial 
infarction, angina pectoris, stroke, coronary artery 
by-pass surgery, percutaneous transluminal coronary 
angioplasty, uncontrollable arterial hypertension (blood 
pressure ≥180/100 mm Hg), medications like digitalis 
or drugs affecting homocysteine metabolism (including 
vitamins), peripheral vascular disease, tobacco smoking, 
alcohol consumption, diagnosis of hepatic and/or 
thyroid disease according to physical examination and 
laboratory findings, arrhythmic or ischemic changes 
in electrocardiogram (ECG) at rest, severe acute or 
chronic disease, serum creatinine >140 mmol/L, and 
presence of retinoangiopathy or nephropathy. Age- and 
sex-matched healthy subjects were chosen as controls. 
Their medical histories, physical examinations, 
routine biochemical and hematological tests and ECG 
records were in normal ranges. They were not on any 
medication (including vitamins) and did not report any 
tobacco or alcohol abuse.
The study covered 50 patients in order to 
investigate the association between plasma CRP and 
Hcy levels, the presence of CHD and incidence of 
cardiovascular events among DMT2 patients. The 
first group consisted of 20 patients with DMT2, 12 
females and 8 males. All of them did not present with 
any clinical, laboratory or instrumental evidence of 
CHD or CVD.  The second group consisted of 20 
patients, 10 males and 10 males, with DMT2 and a 
history of CHD or CVD. The third control group 
consisted of 10 subjects, 5 males and 5 females, 
matched to these groups in terms of age and classical 
risk factors for CHD. Every participant in the study 
signed an informed agreement that was approved by 
the local ethical committee.
The laboratory constellation included serum 
high sensitive CRP (hs-CRP), serum cholesterol, 
HDL-cholesterol, triglycerides, LDL-cholesterol and 
serum Hcy levels.
Venous blood samples were taken from the 
patients after 12-hour fasting. Total cholesterol and 
triglyceride levels were measured by using standard 
commercial enzymatic kits. LDL-cholesterol 
concentration was calculated by Friedewald’s 
formula. Plasma obtained by addition of EDTA and 
centrifugated immediately after collection was used 
for Hcy estimation. Plasma samples were frozen 
and stored at -20°C. Hcy levels were determined by 
polarization immunoassay method using Abbott 
IMX analyser.  Hs-CRP was determined by using 
Pointe scientific test adapted on Hitachi 902.
RESULTS
The laboratory results of the patients and 
controls were shown on Table 1. There were no 
statistically significant differences in the biochemical 
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characteristics, age and body mass index (BMI) of the 
participants except forr the fasting plasma glucose 
concentrations.
Gender distribution of Hcy and hs-CRP values 
in patients and controls were presented on Table 2.
According to these results, it was evident that 
there was a significant difference between the hs-CRP 
concentration (p< 0,001) of DMT2 patients and controls 
as well as between those of group one and group two. 
This was, however, not the case of Hcy. Although 
Hcy concentrations of DMT2 patients were higher 
than those of controls, there was no any statistically 
significant difference (p=0,2). On the other hand, 
Hcy concentrations differed statistically significantly 
(p<0,001) of between group one and group two.
DISCUSSION 
Elevated plasma Hcy and hs-CRP levels are well-
known as independent CVD risk factors. However, 
in the absence of a clear mechanism linking Hcy 
to CVD, there is an ongoing debate whether this 
relationship is a cause or a result of the ongoing 
atherosclerosis. There are a lot of studies indicating 
the role of Hcy as a non-classical independent risk 
factor for CHD, however, information about DM 
patients remains controversial.  Mc Cully was the first 
to draw attention to the relationship between Hcy 
levels and CVD in 1967. This topic has been subject 
to intensive research, especially, because of the easy 
way to control hyperhomocysteinemia by vitamin B, 
folate and nicotinamid acid supplementation.
It has been shown (10) that Hcy levels are 
higher in patients with established macroangiopathy 
which leads to the conclusion that Hcy levels are an 
independent risk factor for CVD in DMT2 patients, 
too. Other authors report that hyperhomocysteinemia 
is by 1,6 times stronger CVD risk factor in DM 
patients than in the common population (8). These 
data and the fact that CVD prevalence in DM patients 
is by 2-4 times higher and remains the leading cause 
for death in this group initiated numerous studies on 
hyperhocysteinemia, DM and CVD. 
Table 1. Laboratory characteristics of patients and controls
Parameter     Group one Group two Group three
Age (years) 54±6 58±2 50±4
Body mass idex (kg/m2) 30±2 31±3 28±3
Fasting plasma glucose (mmol/L) 8,1 8,8 5,2
Total cholesterol (mmol/L) 6,8 7,2 6,5
Triglycerides (mmol/L) 2,7 3,1 2,6
High density cholesterol (mmol/L) 1,1 1,0 1,3
Low density cholesterol (mmol/L) 3,6 3,7 2,4
hs-CRP (mg/L) 3,77 5,8 2,18
Hcy (μmol/L) 8,9 12,66 8,1
Parameter
Group one Group two Group three 
females males females males females males
hs-CRP (mg/L) 3,03 4,2 4,97 5,95 2,1 2,3
Hcy (μmol/L) 10,8 8,2 12,41 9,2 8,95 7,8
Table 2. Gender distribution of Hcy and hs-CRP values in patients and controls
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Our study failed to prove that examining Hcy 
of every DM patient without CHD complication can 
be useful for CHD risk stratification. It is, however, 
obvious that Hcy is a part of the portrait of CHD-
complicated DM patient. Unfortunately, it is not 
possible to give a clear answer to this question with our 
findings yet. Further prospective long-term outcome 
studies will help elucidating the issue whether high 
Hcy levels in DM patients are a primary independent 
risk factor or an early finding of arteriosclerosis.
CONCLUSION
Serum hs-CRP concentrations are significantly 
higher in DMT2 patients than in healthy controls 
as well as in DMT2 patients with CHD than in 
those without CHD. Serum Hcy concentrations are 
significantly higher in DMT2 patients with CHD 
than in controls. Both markers are elevated in the 
highest risk group of DMT2 patients and CHD. Our 
results support the use of hs-CRP as risk stratification 
tool although this assumption can’t be directly 
addressed to Hcy presenting with a questionable 
diagnostic value.
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